We are live on ! Find out more
GILD icon

Gilead Sciences

982 hedge funds and large institutions have $96.8B invested in Gilead Sciences in 2013 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 337 increasing their positions, 440 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 46

39% more funds holding in top 10

Funds holding in top 10: 82114 (+32)

20% more capital invested

Capital invested by funds: $80.8B → $96.8B (+$16B)

4% more funds holding

Funds holding: 948982 (+34)

23% less repeat investments, than reductions

Existing positions increased: 337 | Existing positions reduced: 440

67% less call options, than puts

Call options by funds: $785M | Put options by funds: $2.37B

Holders
982
Holders Change
+34
Holders Change %
+3.59%
% of All Funds
31.83%
Holding in Top 10
114
Holding in Top 10 Change
+32
Holding in Top 10 Change %
+39.02%
% of All Funds
3.7%
New
88
Increased
337
Reduced
440
Closed
46
Calls
$785M
Puts
$2.37B
Net Calls
-$1.58B
Net Calls Change
-$165M
Name Holding Trade Value Shares
Change
Change in
Stake
FCAM
201
F&C Asset Management
United Kingdom
$37.7M +$427K +7,144 +1%
Nisa Investment Advisors
202
Nisa Investment Advisors
Missouri
$36.3M -$946K -15,831 -3%
FMI
203
Factory Mutual Insurance
Massachusetts
$35.8M
ACI
204
AMP Capital Investors
Australia
$35.5M +$4.24M +70,903 +15%
MSA
205
Mason Street Advisors
Wisconsin
$34.9M -$13.2M -221,450 -29%
PP
206
Prudential plc
United Kingdom
$34.6M +$16.5M +275,700 +100%
Mirae Asset Global Investments
207
Mirae Asset Global Investments
South Korea
$34M +$1.4M +23,402 +5%
GI
208
GLG Inc
New York
$33.8M +$21.2M +354,253 +193%
BHC
209
Bowen Hanes & Co
Florida
$33.7M -$5.68M -95,020 -15%
CAM
210
ClariVest Asset Management
California
$33.5M -$5.65M -94,515 -15%
RG
211
Redmile Group
California
$33.3M +$31.7M +529,800 New
TSU
212
TD Securities (USA)
New York
$32.9M +$237K +3,962 +0.8%
OC
213
Oppenheimer & Co
New York
$32.8M +$2.21M +36,913 +8%
RG
214
Renaissance Group
Kentucky
$32.6M -$1.38M -23,011 -4%
Public Sector Pension Investment Board (PSP Investments)
215
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$32.1M -$873K -14,600 -3%
KeyBank National Association
216
KeyBank National Association
Ohio
$31.9M -$57.1M -956,213 -65%
SAM
217
Sentinel Asset Management
Vermont
$31.9M -$58.6K -980 -0.2%
TP
218
Third Point
New York
$31.4M +$29.9M +500,000 New
Asset Management One
219
Asset Management One
Japan
$31.4M -$5.88M -98,341 -17%
SG
220
Swarthmore Group
Pennsylvania
$31.2M -$3.16M -52,825 -10%
ProShare Advisors
221
ProShare Advisors
Maryland
$31.1M -$5.95M -99,564 -17%
PWLP
222
Prio Wealth Limited Partnership
Massachusetts
$30.4M -$887K -14,833 -3%
AQR Capital Management
223
AQR Capital Management
Connecticut
$29.5M -$8.58M -143,586 -23%
PIM
224
Partner Investment Management
California
$28.6M -$10M -167,913 -27%
HIMCH
225
Hartford Investment Management Co (HIMCO)
Connecticut
$28.6M -$866K -14,483 -3%

GILD Hedge Fund Activity: Q3 2013 in Review

982 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2013, worth a combined $96.8B — up 20% from $80.8B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new GILD positions and 46 closed out — a net gain of 42 holders — while 337 added to existing stakes and 440 trimmed.

The largest buyer was Montag & Caldwell, opening a new position worth an estimated $230M. The largest seller was Capital World Investors, cutting an estimated $397M.

  • 982 institutional investors held Gilead Sciences (GILD) as of Q3 2013, up from 948 in Q2 2013.
  • Funds reported $96.8B of Gilead Sciences stock for Q3 2013, up 20% quarter-over-quarter.
  • 88 funds opened new Gilead Sciences positions in Q3 2013 and 46 closed out, a net change of +42 holders.
  • The largest Gilead Sciences buyer in Q3 2013 was Montag & Caldwell, an estimated $230M added.
  • The largest Gilead Sciences seller in Q3 2013 was Capital World Investors, an estimated $397M sold.

Based on aggregated 13F filings for Q3 2013.